You are here: Industry Insights > Pemazyre

News List

NICE recommends Incyte’s Pemazyre for rare bile duct cancer pharmatimes
July 23, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Incyte Biosciences UK’s Pemazyre for the treatment of the rare bile duct cancer cholangiocarcinoma (CCA).
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan, China Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a F prnasia
June 22, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the Taiwan, China market has
Inctye’s Pemazyre authorised in the EU for bile duct cancer pharmatimes
March 30, 2021
The European Commission (EC) has approved Incyte’s kinase inhibitor Pemazyre for the treatment of certain patients with advanced cholangiocarcinoma, also known as bile duct cancer.
FDA approves Incyte’s Pemazyre as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma pharmaceutical-business-review
April 22, 2020
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre™ (pemigatinib).
FDA Approves First Targeted Treatment for Cholangiocarcinoma americanpharmaceuticalreview
April 21, 2020
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Pemazyre (pemigatinib), the first treatment approved for adults with certain types of previously treated, advanced cholangiocarcinoma.
US clears first targeted treatment for cholangiocarcinoma pharmatimes
April 20, 2020
US regulators have approved Incyte's Pemazyre as the first targeted treatment for cholangiocarcinoma.